Ratings HBM Healthcare Investments AG

Equities

HBMN

CH0012627250

Market Closed - Swiss Exchange Other stock markets 11:30:41 2023-12-08 am EST			5-day change	1st Jan Change
170 ^CHF	-2.30%		-2.86%	-15.42%

Dec. 01	AbbVie to Buy Cancer-focused ImmunoGen for $10.1 Billion	MT
Nov. 21	Kepler Cheuvreux Lowers Price Target on HBM Healthcare Investments, Maintains Buy Recommendation	MT

Summary

According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The company appears to be poorly valued given its net asset value.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The valuation of the company is particularly high given the cash flows generated by its activity.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector : Investment Management & Fund Operators

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HBM HEALTHCARE INVESTMENTS AG	-15.42%	1 342 M $		D+
UMBRA COMPANIES INC.	-37.60%	9 147 M $	-	-
HERCULES CAPITAL, INC.	+16.94%	2 308 M $		B-
OCTOPUS TITAN VCT PLC	-23.98%	1 289 M $	-	-
CION INVESTMENT CORPORATION	+12.41%	595 M $		-
VERUSA HOLDING A.S.	+110.05%	556 M $	-	D+
MOLTEN VENTURES PLC	-29.02%	543 M $		B+
OCTOPUS APOLLO VCT PLC	+4.13%	459 M $	-	-
WOORI TECHNOLOGY INVESTMENT CO., LTD	+89.07%	420 M $	-	-
GOZDE GIRISIM SERMAYESI YATIRIM ORTAKLIGI A.S.	+36.24%	382 M $	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes